BrainsWay reports promising results for accelerated depression treatment

BrainsWay (BWAY) announced preliminary trial results indicating its accelerated Deep TMS protocol for major depressive disorder shows comparable efficacy to standard treatment but requires fewer clinic visits; patients reached remission in a median of 21 days versus 28 days with standard treatment. The company also reported Q1 2025 revenues of $11.5 million and EPS of $0.03, aligning with estimates, leading H.C. Wainwright to raise its 2025 revenue forecast to $51.6 million while maintaining a Buy rating with a $16 price target. Additionally, BrainsWay invested $5 million in Stella MSO, LLC, to expand the reach of its Deep TMS Therapy.

Analysis

BrainsWay Ltd. (BWAY) has announced encouraging preliminary results from a multicenter trial for its accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol for major depressive disorder. The study, involving 104 adult patients, suggests the accelerated protocol achieves comparable efficacy to standard treatment in depression score reduction (18.9 points versus 19.9 points for standard) and nearly identical response rates (87.8% for accelerated versus 87.5% for standard). However, a notable difference exists in remission rates, with the accelerated protocol showing 78.0% compared to 87.5% for standard treatment. Despite this, the accelerated protocol offers substantial patient benefits, including fewer clinic visits (five sessions daily over six days, followed by eight continuation sessions over four weeks), significantly shorter session durations (under 10 minutes versus 20 minutes), and a faster median time to remission (21 days versus 28 days). It is crucial to note this protocol remains investigational, is not yet FDA-cleared, and the results are subject to further analysis and peer review. This clinical development complements BrainsWay's recent financial performance; the company reported Q1 2025 revenues of $11.5 million and EPS of $0.03, aligning with analyst expectations. Consequently, H.C. Wainwright raised its full-year 2025 revenue forecast for BWAY to $51.6 million (from $50.8 million) and its 2026 estimate to $60.8 million (from $60 million), maintaining a Buy rating and a $16.00 price target. BrainsWay management reaffirmed its 2025 revenue guidance of $49-51 million. The company's strong financial position, evidenced by more cash ($71.6 million at Q1-end) than debt and a current ratio of 5.03, supports strategic initiatives like its recent $5 million minority stake investment in Stella MSO, LLC, aimed at expanding Deep TMS therapy reach. This positive operational and clinical news, reflected in a 'strongly positive' sentiment score of 0.85 and a specific BWAY sentiment of 0.9, has contributed to the stock's 74% return over the past year, trading near its 52-week high.

Key Decisions for Investors

• Investors should consider the potential market expansion and increased patient accessibility if the accelerated Deep TMS protocol receives FDA clearance, balanced against the preliminary nature of the trial data and the observed lower remission rate compared to standard treatment.
• The company's robust financial health, consistent Q1 earnings, and upwardly revised revenue forecasts from analysts like H.C. Wainwright provide a positive backdrop, yet the stock trading near its 52-week high may indicate that some optimism is already priced in.
• Monitor upcoming catalysts, particularly further clinical trial data, progress towards FDA clearance for the accelerated protocol, and the successful integration and performance of strategic investments like Stella MSO in expanding treatment accessibility.